Overall, these anti-VM miRNAs interfere with multiple oncogenic pathways, including IL-6/STAT3, AXL, ZEB1, and HIF-1α, underscoring the multifaceted regulatory landscape of miRNA-mediated VM control in breast cancer. The gene discussed is HIF1A; the disease is breast carcinoma.